Status:

RECRUITING

Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

Lead Sponsor:

Vanda Pharmaceuticals

Conditions:

Social Anxiety Disorder (SAD)

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorde...

Detailed Description

The study will enroll approximately 500 patients with current diagnosis of social anxiety disorder (SAD). Eligible participants will be randomly assigned to receive either a single oral dose of VQW-76...

Eligibility Criteria

Inclusion

  • Ability and willingness to provide written informed consent.
  • Male and female subjects aged 18-65 years, inclusive.
  • Current diagnosis of social anxiety disorder.
  • Liebowitz Social Anxiety Scale total score ≥60.
  • Public Speaking Anxiety Scale total score ≥60.
  • Hamilton Depression Rating Scale score ≤18.

Exclusion

  • Suicide attempts and/or suicidal ideation in the past 2 years or currently at risk of suicide in the opinion of the investigator.
  • History of bipolar disorder, schizophrenia, psychosis, seizures, delusional disorders, obsessive-compulsive disorder, or autism spectrum disorder.
  • Posttraumatic stress disorder or an eating disorder in the past 6 months.
  • Substance or alcohol use disorder in the past 6 months or positive in drug/alcohol screening.
  • Psychotherapy in the past 6 months.
  • Psychotropic medication in the past 2 months.
  • Current or planned pregnancy or nursing during the trial period.
  • Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit of study participation, or interference with study objectives.

Key Trial Info

Start Date :

September 22 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2027

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT07221578

Start Date

September 22 2025

End Date

April 1 2027

Last Update

December 5 2025

Active Locations (20)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (20 locations)

1

Vanda Investigational Site

Phoenix, Arizona, United States, 85012

2

Vanda Investigational Site

Scottsdale, Arizona, United States, 85260

3

Vanda Investigational Site

Encino, California, United States, 91316

4

Vanda Investigational Site

Newport Beach, California, United States, 92660